24th Workshop on Methods in Clinical Cancer Research

15 – 21 June 2024 – Sint Michielsgestel, Netherlands

MCCR - Partners logos

Online application procedure

Application open - Illustration
Application close - Illustration
  • Applications will only be accepted from those based in Europe (EU and non-EU), as well as the Mediterranean and Middle East regions.
  • Applications from Eastern Europe and lower-middle-income economies (according to the World Bank listing) in the above regions are encouraged. Successful applicants from these categories may be eligible for a fee waiver.
  • Applications should be for original clinical trials, not studies to be embedded in already running trials.
  • Candidates must have completed one year of clinical training at the time of application and be within five years of completion of Residency/Fellowship training in one of the following disciplines:
    • Junior clinician specialising in oncology;
    • Junior health care professional managing cancer patients (i.e. dermatologist, gynaecologist, haematologist, neuro-oncologist, urologist);
    • Junior radiologist or pathologist with a strong involvement in cancer care.
  • Candidates must:
    • Have a major interest in clinical research and intend to develop a career in that field;
    • Aim to write and conduct a clinical protocol for a study not previously performed, nor written, which is also considered feasible within the institutional setting and the time of completion of the candidate’s clinical training;
    • Have support of the Direct Supervisor/Mentor and sustained commitment in the years following the Workshop;
    • Be fluent in written and spoken English and have good computer skills.
  • The organisers of this Workshop, the annual Vail Workshop (USA) and the biannual ACORD Workshop (Australia) would like to highlight that applications should only be submitted for attendance to one of these Workshops. Submission of this application implies that you have not applied and/or been selected to the other workshops.

Applications will not be accepted if the above criteria are not fulfilled.

The online application form asks for the following:

  • Personal details and contact information
  • One-page description of the clinical therapeutic trial protocol you intend to write during the Workshop
  • C.V.
  • Statement of motivation outlining the reasons for wanting to participate in this workshop
  • Statement from the Direct Supervisor/Mentor in support of the applicant, describing their commitment to long-term follow-up and facilitation of the actual implementation of the study designed at the workshop
Applications to participate in the Workshop can only be submitted electronically, via the Apply Now button.

Applicants will be asked to sign in with their EORTC Event profile credentials or create an account if they do not have a profile yet.

The required information does not need to be entered all at once. The application form can be saved at any moment in the process and applicants can return to the form at a later stage.

Applicants must ensure the application form is correctly completed prior to submission.

A confirmation of receipt of application will be sent within 48 hours.

Applications received after the submission deadline will not be accepted.

Participation to the MCCR Workshop is limited to 80 applicants.

The Workshop Review Committee will evaluate the applications and base its decision on a number of factors including:

  • Quality and feasibility of the proposed protocol concept and the letters of commitment submitted;
  • Individual career path in medical training and competence in clinical cancer research;
  • Support of relevant departments and/or institutions to help conduct the clinical trial.

The selection of applications is at the sole discretion of the Workshop Review Committee. Whilst feedback on the application process and selection is welcome, the Workshop Review Committee will not enter into any discussions regarding the final decision.

Applicants will be notified of the status of their application after mid-March 2024.